However, in the last decade, second-generation androgen-receptor (AR) signaling inhibitors (i.e., enzalutamide) and intra-tumor androgen synthesis inhibitors (i.e., abiraterone) have been approved for the treatment of mCRPC with improved survival benefits. The gene discussed is AR; the disease is neoplasm.